ClinicalTrials.gg
WithdrawnNCT03331848ATTUNEDUpdated Mar 22, 2018

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

A Phase 2 interventional study of Placebo oral capsule and PXT002331 - 20mg in Parkinson Disease, sponsored by Prexton Therapeutics. Withdrawn. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-03-22.

Sponsored by Prexton Therapeutics (part of H. Lundbeck A/S) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Parkinson Disease by H. Lundbeck A/S — 2 open to participants now, 2 under way, none of them phase 3. Parkinson Disease · H. Lundbeck A/S.

Enrollment
21st of 21
0 · median 64
Started
2018
with 1 other
Phase 2
4 of 21
1 open now
Registered
13th of 21
by date

Among the 21 studies in Parkinson Disease by H. Lundbeck A/S, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 2, and was the 13th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

2 of the 21 studies in Parkinson Disease by H. Lundbeck A/S are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Parkinson Disease by H. Lundbeck A/S, or all of them as a file.
02

Study summary

This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Levodopa-Induced Dyskinesia (LID)
  • Foliglurax
  • Parkinson's Disease
  • mGlu4 PAM
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 35 and 85 years of age, inclusive, at the time of signing
  • Diagnosed after the age of 30 years with idiopathic PD
  • A documented medical history of idiopathic PD for at least 3 years
  • Disease severity of 2 to 4 on the modified Hoehn and Yahr scale when in the OFF state
  • Been treated with a stable regimen of levodopa-containing therapy
  • Subjects must be receiving at least 3 doses per day of levodopa-containing therapy, and must be on a stable dose for at least 2 weeks for immediate-release levodopa or at least 6 weeks for prolonged-release levodopa preparations prior to the first screening visit
  • Experienced LID over a period of at least 3 months prior to randomization
  • If needed, in the opinion of the investigator, subjects must have a caregiver
  • Female subjects will be women of non-

Exclusion criteria

Exclusion Criteria:

  • Patient is currently participating in or has participated in another study in the last 3 months
  • Subjects with atypical, secondary, or drug-induced Parkinsonism
  • Subjects with a history of dyskinesia that was exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic without peak-dose dyskinesia
  • Subjects with a score of \<25
  • Subjects who have, or who had a history of, any hepatic or gallbladder disorder, as determined by the investigator
  • Subjects who have dementia, currently active psychosis, or hallucinations.
  • Suicide attempt within 1 year prior to the first screening visit, or severe suicidal ideation within 6 months prior to the first screening visit
  • Subject has a current diagnosis of epilepsy,
  • Any known to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma
  • Carcinoma or successfully treated squamous cell carcinoma of the skin and no sing of disease recurrence for at least 5 years
  • Subjects who have had a clinically significant illness within 4 weeks before the first dose, as determined by the investigator
  • Subjects with scheduled surgeries/hospitalizations during the study period
  • Any advanced, severe, or unstable disease (other than PD) that may interfere with the primary and secondary study outcome evaluations
  • Subjects who have undergone prior neurosurgical operation for PD,
  • Subjects currently taking (or expected to be administered during the course of the study) any of the prohibited medications (amantadine, safinamide, dopamine-antagonists).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    PLACEBO

    Drug: Placebo oral capsule

  • Experimental
    PXT002331 - 20mg

    Drug: PXT002331 - 20mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Unified Dyskinesia Rating Scale (UDysRS) total score in subjects with PD experiencing levodopa-induced dyskinesia.

    Time frame: 26 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2018; primary completion for Feb 2019, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2017
First posted
Nov 6, 2017
StartEst.
Jan 15, 2018
Primary completionEst.
Feb 1, 2019
CompletionEst.
Feb 1, 2019
Last update
Mar 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03331848
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Jan 15, 2018 (estimated)
Primary completion
Feb 1, 2019 (estimated)
Completion
Feb 1, 2019 (estimated)
Last update
Mar 22, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foliglurax

Start the discussion